文献速递消化系统肿瘤

评估白蛋白结合型紫杉醇联合吉西他滨治疗ECOG体力状态评分为2的胰腺癌患者的疗效与安全性的I/II期试验

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
PubMed 文献 · J Clin Oncol · 2018-12-04

本研究在ECOG体力状态评分为2的转移性胰腺导管腺癌患者中,先随机比较四种GA方案耐受性,选出B、D两方案进入II期,共入组221例。B、D两方案6个月总生存率分别为63%和69%,无显著差异,耐受性可接受。

要点

  • B方案(白蛋白结合型紫杉醇100 mg/m²联合吉西他滨)与D方案(125 mg/m²联合吉西他滨)在体力状态差的患者中耐受性可接受。
  • B、D两方案6个月总生存率分别为63%和69%,无显著差异。
  • B、D两方案最常见的3/4级毒性为中性粒细胞减少(32%和30%)和乏力(14%和16%)。

核心结论

  • 白蛋白结合型紫杉醇100或125 mg/m²联合吉西他滨,于每28天周期的第1、8、15天给药,在转移性胰腺导管腺癌且体力状态差的患者中耐受性良好,安全性和疗效可接受。

研究设计与样本

  • I期部分将患者随机分配至四个平行GA治疗组(每组6例):A组为白蛋白结合型紫杉醇150 mg/m²联合吉西他滨1000 mg/m²双周方案;B组为白蛋白结合型紫杉醇100 mg/m²联合吉西他滨1000 mg/m²标准方案(用药3周停1周);C组为白蛋白结合型紫杉醇125 mg/m²联合吉西他滨1000 mg/m²双周方案;D组为白蛋白结合型紫杉醇125 mg/m²联合吉西他滨1000 mg/m²标准方案。
  • 根据预设标准,耐受性更好的两个方案进入II期部分,主要终点为6个月生存率。
  • II期部分共入组221例患者,B组111例,D组110例。

主要发现

  • B组和D组的中位年龄分别为71岁和68岁,男性比例分别为51%和55%,转移性疾病比例分别为88%和84%,基线特征均衡。
  • B组和D组最常见的3/4级毒性:贫血分别为12%和7%,中性粒细胞减少分别为32%和30%,血小板减少分别为7%和11%,乏力分别为14%和16%,神经毒性分别为11%和16%。
  • B组和D组的缓解率分别为24%和28%,中位无进展生存期分别为5.7个月和6.7个月,6个月总生存率分别为63%和69%,均无显著差异。

关键数值与推荐

  • B组和D组的6个月总生存率分别为63%和69%,无显著差异。
  • B组和D组的缓解率分别为24%和28%,无显著差异。
  • B组和D组的中位无进展生存期分别为5.7个月和6.7个月,无显著差异。

临床怎么用

  • 原文结论认为,白蛋白结合型紫杉醇100或125 mg/m²联合吉西他滨于每28天周期的第1、8、15天给药,在转移性胰腺导管腺癌且体力状态差的患者中耐受性良好,安全性和疗效可接受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gemcitabine plus nanoparticle albumin-bound (NAB) paclitaxel (GA) significantly improved survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and a Karnofsky performance status (PS) of 70% or greater. Because of the low number of patients with reduced PS, the efficacy of this regimen in fragile patients remains unclear. This study aimed to evaluate the efficacy and tolerability of different GA dosing regimens in patients with a poor PS. PATIENTS AND METHODS: In the phase I part of this study, patients were randomly assigned to one of the following four parallel GA treatment arms (six patients per arm): a biweekly schedule of NAB-paclitaxel (150 mg/m2 [arm A] or 125 mg/m2 [arm C]) plus gemcitabine 1,000 mg/m2 or a standard schedule of 3 weeks on and 1 week off of NAB-paclitaxel (100 mg/m2 [arm B] or 125 mg/m2 [arm D]) plus gemcitabine 1,000 mg/m2. The two regimens with the better tolerability profile on the basis of predefined criteria were evaluated in the phase II part of the study, the primary end point of which was 6-month actuarial survival. RESULTS: Arms B and D were selected for the phase II part of the study. A total of 221 patients (111 patients in arm B and 110 patients in arm D) were enrolled. Baseline characteristics including median age (71 and 68 years in arms B and D, respectively), sex (51% and 55% men in arms B and D, respectively), and metastatic disease (88% and 84% in arms B and D, respectively) were comparable between arms. The most frequent grade 3 or 4 toxicities in arms B and D were anemia (12% and 7%, respectively), neutropenia (32% and 30%, respectively), thrombocytopenia (7% and 11%, respectively), asthenia (14% and 16%, respectively), and neurotoxicity (11% and 16%, respectively). In arms B and D, there were no significant differences in response rate (24% and 28%, respectively), median progression-free survival (5.7 and 6.7 months, respectively), and 6-month overall survival (63% and 69%, respectively). CONCLUSION: NAB-paclitaxel administered at either 100 and 125 mg/m2 in combination with gemcitabine on days 1, 8, and 15 every 28 days is well tolerated and results in acceptable safety and efficacy in patients with metastatic pancreatic ductal adenocarcinoma and a poor PS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Macarulla T, Pazo-Cid R, Guillén-Ponce C, et al. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. J Clin Oncol. 2018. PMID: 30523758. doi:10.1200/JCO.18.00089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。